8-K: Immunovant Reports Strong Graves' Disease Remission Data

Immunovant's batoclimab shows durable, treatment-free remission in uncontrolled Graves' disease patients, with registrational trials for IMVT-1402 underway.

Summary

• Immunovant, a Roivant subsidiary, announced positive six-month off-treatment data for batoclimab in uncontrolled Graves' disease (GD) patients.
• Approximately 80% (17 out of 21) of patients who completed the off-treatment follow-up period maintained normal thyroid function (T3 and T4 below the upper limit of normal).
• Of these 17 responders, about 50% (8 patients) achieved anti-thyroid drug (ATD) free remission six months after batoclimab treatment ended.
• An additional 30% (5 patients) were on low ATD doses (2.5 mg/day) after six months off-treatment.
• Batoclimab was well-tolerated with no new safety signals observed, consistent with previous studies.
• Two potentially registrational global trials for Immunovant's lead compound, IMVT-1402, in Graves' disease are currently enrolling, with topline readouts anticipated in 2027.
• The IMVT-1402 trials will use a continuous 600 mg weekly subcutaneous dose for up to 52 weeks, an optimization based on batoclimab's phase 2 learnings.

Sentiment

Score: 9

Explanation: The clinical trial results for batoclimab in Graves' disease are highly positive, demonstrating strong durability and the first-ever observed ATD-free remission, indicating potential disease modification. This addresses a significant unmet need and positions IMVT-1402 for potentially transformative impact. The ongoing registrational trials and optimized design further bolster confidence.

Positives

• Batoclimab demonstrated strong durability of response, with ~80% (17/21) of patients maintaining normal thyroid function six months after treatment cessation.
• Achieved first-ever observed anti-thyroid drug (ATD) free remission in uncontrolled Graves' disease patients, with ~50% (8/17) of responders remaining off all medications.
• The data suggests batoclimab could be the first potentially disease-modifying therapy for uncontrolled Graves' disease.
• Safety and tolerability profile of batoclimab was consistent with prior studies, with no new safety signals identified.
• The design of the IMVT-1402 registrational trials is optimized for potentially improved efficacy, utilizing a continuous high dose.
• Graves' disease represents a high unmet medical need with a significant market opportunity, including 65,000 annual incident uncontrolled patients and a large prevalent pool.

Negatives

• The batoclimab study used a suboptimal step-down dosing design (680 mg QW for 12 weeks, then 340 mg QW for 12 weeks), which may have limited full efficacy potential.
• While 50% achieved ATD-free remission, 24% of responders at Week 48 were still on ATD doses >2.5 mg/day.
• The data presented is from a proof-of-concept study (Phase 2), and registrational trials for IMVT-1402 are still ongoing with topline data not expected until 2027.

Risks

• Initial results or preliminary analyses from early clinical trials may not be predictive of final trial results or results of later clinical trials.
• Results from animal studies may not be predictive of results in humans.
• The timing and availability of data from clinical trials are subject to uncertainty.
• Discussions with regulatory agencies, as well as regulatory submissions and potential approvals, may not occur within expected timelines or at all.
• Future clinical trials may not confirm any safety, potency, or other product characteristics described or assumed.
• Any product candidate developed may not progress through clinical development or receive required regulatory approvals.
• Product candidates may not be beneficial to patients, or, if approved, may not be successfully commercialized.
• Global factors such as geopolitical tensions and adverse macroeconomic conditions could affect business operations and supply chains, including clinical development plans and timelines.
• Immunovant's business is heavily dependent on the successful development, regulatory approval, and commercialization of batoclimab and IMVT-1402.
• Immunovant will require additional capital to fund its operations and advance IMVT-1402 and batoclimab through clinical development.

Future Outlook

Immunovant expects IMVT-1402 to potentially be the first-in-class disease-modifying therapy for Graves' disease, with two registrational trials currently enrolling and topline readouts anticipated in 2027. The company believes these data have the potential to be transformative for patients and practice-changing for physicians if approved by the FDA, addressing a significant unmet need. The optimized trial design for IMVT-1402 is expected to generate improved efficacy data.

Management Comments

• "These novel and encouraging results support FcRn blockade as a potentially effective mechanism for the treatment of Graves disease, with the six-month remission data providing evidence of potential disease modification." George Kahaly, M.D., Ph.D., Lead Principal Investigator.
• "We are incredibly excited to present these remission data demonstrating strong durability of response and ATD-free remission in previously uncontrolled patients off-treatment for six months." Eric Venker, M.D., Pharm.D., CEO of Immunovant.
• "We believe these data have the potential to be transformative for patients and practice-changing for physicians, if approved by FDA, by addressing a significant unmet need in Graves disease." Eric Venker, M.D., Pharm.D., CEO of Immunovant.

Industry Context

Graves' disease is a classic autoimmune condition with a high unmet need, as 25-30% of patients are relapsed, uncontrolled, or intolerant to current anti-thyroid drugs (ATDs). There is no existing disease-modifying therapy, and ablative options are being used less frequently. Patients with uncontrolled Graves' disease face a higher risk of severe comorbidities like cardiovascular events, thyroid eye disease (TED), and thyroid storm. Immunovant's batoclimab, and its successor IMVT-1402, aim to address this gap by offering a potentially disease-modifying therapy, which could significantly shift the treatment paradigm away from symptomatic management or ablation. The market opportunity includes an annual incident population of 65,000 uncontrolled patients and a large untapped prevalent pool.

Comparison to Industry Standards

• The observed ATD-free remission in uncontrolled Graves' disease patients is described as "first-ever," indicating a significant advancement beyond current industry standards which primarily rely on anti-thyroid drugs (ATDs) for symptomatic control or ablative therapies.
• Current treatments for Graves' disease, such as ATDs, often lead to relapse or intolerance in 25-30% of patients, and ablative options (radioactive iodine or surgery) are associated with permanent hypothyroidism and are increasingly less favored by patients and physicians.
• The potential for disease modification with batoclimab, as evidenced by sustained normal thyroid function and ATD-free remission six months post-treatment, contrasts with existing therapies that do not offer a disease-modifying effect.
• The company highlights a "significant unmet need" in Graves' disease, implying that current therapeutic options are insufficient for a substantial portion of the patient population.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical data, potential for a first-in-class disease-modifying therapy, and advancement towards registrational trials, which could lead to significant market opportunities and increased company valuation.
• Patients with Graves' Disease: Highly positive impact as the therapy offers potential for durable, treatment-free remission and disease modification, addressing a significant unmet need and improving quality of life by reducing reliance on daily medications or avoiding ablative procedures.
• Physicians: Potential for a new, transformative treatment option that could change clinical practice by offering a disease-modifying therapy for uncontrolled Graves' disease patients.
• Regulatory Authorities: The novel data and potential for disease modification will be of significant interest, potentially streamlining future review processes if subsequent trials confirm these findings.

Next Steps

• Immunovant will present an abstract with six-month off-treatment data at the 2025 Annual Meeting of the American Thyroid Association (ATA) on September 11, 2025.
• Roivant will host a conference call and webcast on September 3, 2025, at 4:30 p.m. EDT to discuss the Immunovant data.
• Continue enrollment in two potentially registrational global trials for IMVT-1402 in Graves' disease.
• Anticipate topline readouts from the IMVT-1402 registrational trials in 2027.

Key Dates

Recommendation

The reported six-month off-treatment remission data for batoclimab in uncontrolled Graves' disease patients is exceptionally strong, demonstrating both high durability of response (~80%) and, critically, the first-ever observed anti-thyroid drug (ATD) free remission in a substantial portion of responders (~50%). This indicates a potential for disease modification, a significant breakthrough in a condition with high unmet medical need and no existing disease-modifying therapies. The progression to two registrational trials for IMVT-1402, with an optimized dosing strategy and topline data expected in 2027, de-risks the development pathway. Given the large market opportunity and the transformative potential of this therapy, the news is highly positive and warrants a strong buy recommendation for long-term investors.

Keywords

Graves Disease, Immunovant, Roivant Sciences, Batoclimab, IMVT-1402, Autoimmune Disease, FcRn Inhibitor, Clinical Trial, Remission Data, Thyroid Disease, Biopharmaceutical, Drug Development, Phase 2, Registrational Trials